Welcome!The Maryland and District of Columbia Society of Clinical Oncology, Inc. (“MDCSCO”) is committed to improving the quality and delivery of care in medical oncology in the State of Maryland and the District of Columbia. We promote appropriate standards of care in oncology and cooperate with investigators conducting cancer research. In addition, we assist in the continuing education of oncologists and educate the public, the government, insurance carriers, and other health care providers about appropriate prevention of cancer and other therapeutic options for patients with cancer. We encourage you to join more than 250 current members in providing the leadership in our progressive future. Click here to find out more about our membership.
VIEWBOOK
|
|
IMPORTANT NOTICE TO ONCOLOGISTS
NO MORE DUES!
The Maryland and District of Columbia Society of Clinical Oncology now offers FREE professional memberships to physician oncologists. Click here for the flyer. As a member, you get the following benefits:
|
CMS Releases Physician Fee Schedule Final Rule
The Centers for Medicare and Medicaid Services (CMS) released the final CY 2019 Physician Fee Schedule (PFS) rule. The agency responded to the overwhelming negative stakeholder response to its proposal to revise evaluation and management (E/M) documentation requirements and payment by significantly revising its final policy.
Click here for more.
CMS Releases Final Hospital Outpatient Payment Rule - The Centers for Medicare and Medicaid Services (CMS) released the final CY 2019 Hospital Outpatient Prospective Payment System (OPPS) rule. In the Society’s comment letter, ASH requested that CMS change the status indicator for the four new Category III CPT codes for chimeric antigen receptor (CAR) T-cell therapy from “B” to “S.” In the final rule, CMS did finalize this change for one of the four codes, code 0540T, CAR-T cell administration, autologous.
Click here for the report.
UPCOMING MEETINGS
November 14, 2018 - CME Event
Gary Cohen, MD, FACP, FASCO
Director Emeritus, Sandra and Malcolm Berman Cancer Institute
GBMC
Associate Professor
Johns Hopkins Oncology
Topic: The Transition from Biologics to Biosimilars in Oncology Treatment Paradigms
A Means to Reduce Healthcare Costs with Continued Effective Management of Patients
Location: Baltimore Marriott Inner Harbor at Camden Yards
Promenade Room
110 S. Eutaw Street
Baltimore, MD
CME : 1 Credit
6:30 - Reception
7:30 - Dinner followed by Program
No charge to MDCSCO members
Open to industry, but no displays
MORE INFORMATION
REGISTER ONLINE HERE
Industry Spotlight
December 5, 2018
6:15 pm - 9:45 pm
Session with Board for Platinum, Emerald, and Diamond Corporate Members Only
Hotel at Arundel Preserve
7795 Arundel Mills Blvd.
Hanover, MD
ANNOUNCEMENTS
Click here for more.
Make connections that drive hematology and your career forward.
With more than 25,000 attendees, the ASH annual meeting is the best place to connect with hematology professionals from around the world. It’s not uncommon for connections made at the meeting to lead to new jobs, research opportunities, or important collaborations that help advance the field of hematology.
But what are the best opportunities for networking at the ASH annual meeting?
Quality Payment Program: 2018 CME Modules, Infographics, and Scoring Guide
The Centers for Medicare & Medicaid Services (CMS) posted three new Continuing Medical Education (CME) modules on the Medicare Learning Network Learning Management System for the 2018 Merit-based Incentive Payment System (MIPS), Click here to see more.
Corporate Members
PR Newswire
Affiliates
ASCO has announced fifteen distinguished members selected by the Nominating Committee as candidates for open leadership positions within the Society. From November 1 to December 3, 2018, eligible ASCO members are encouraged to vote to choose new leaders and on proposed amendments to the ASCO Bylaws. To learn more about the candidates, click here and log into your ASCO account.
News
Breaking: Major Changes to Part B Proposed by Trump Administration
Yesterday, the Trump Administration unveiled a sweeping proposal to overhaul Medicare Part B payment as part of efforts to address the high and unsustainable prices of prescription drugs in the U.S.
The proposal would set Part B payments based on the discounts manufacturers offer in other countries. Participation would cover 50 percent of the country and be mandatory in randomized geographic regions.
Click here for more.